Expedition Therapeutics
Expedition Therapeutics raises $165M Series A at $700M valuation
Quick Facts
Expedition Therapeutics: Series A Funding Round
Expedition Therapeutics has successfully raised $165M in Series A funding, reaching a valuation of $700M.
Company Overview
Developer of therapies for inflammatory and respiratory diseases
Funding Details
The Series A round was led by Foresite Capital, with participation from Casdin Capital.
Company Information
- Headquarters: San Francisco, CA
- Founded: 2024
- Employees: 60+
- Category: Biotech
Investment
Expedition Therapeutics plans to use the funds to accelerate product development, expand its team, and scale operations globally.
About the Investors
- Foresite Capital: Verified investor in Series A
- Casdin Capital: Verified investor in Series A
Key Investors
About the Author
Related Company Reports
Torl Biotherapeutics raises $96M Series C at $500M valuation
Torl Biotherapeutics raises $96M in Series C at $500M valuation. Antibody-based immunotherapies for cancer patients...
Nilo Therapeutics raises $101M Series A at $450M valuation
Nilo Therapeutics raises $101M in Series A at $450M valuation. Developing therapies based on neuro-immunology research...
Arthrosi Therapeutics raises $153M Series E at $800M valuation
Arthrosi Therapeutics raises $153M in Series E at $800M valuation. Developing next-generation gout treatment drug for chronic conditions...